The China Trap: Why Asian Healthcare Leaders Should Look West, Not East, for Growth and Investment
For decades, China has been seen as one of the prime destinations for global business expansion. Its size, manufacturing capacity, and rapid modernisation made it ideal for Asian enterprises to stay close, save costs, and access a vast, growing market. This thinking made a lot of sense in healthcare. China's aging population, rising healthcare costs, and need for innovation made it an attractive place for hospitals, medtech companies, and digital health platforms to establish themselves.
The perspective is shifting
These perceptions are changing because of the significant shift in the geopolitical relationship between China and the U.S. People who once believed in the strength of economic ties now see the two nations in a long-term, zero-sum strategic competition. Many Asian healthcare companies are now caught in the "China trap": they are overly invested in a market who’s political and legislative landscape is moving away from global capital, innovation ecosystems, and strategic stability.
Patrick McGee's 2025 book "Apple in China" brought this Catch-22 into focus. It discusses how the world's most valuable brand became overly dependent on an unpredictable, authoritarian government. This article serves as a warning for Asian healthcare firms looking to expand internationally.
Unstable Geopolitics
The U.S.-China relationship remains crucial, but regional security concerns make it even riskier to overly depend on China. As a student at the London School of Economics in 2014, I, like most people worldwide, viewed the China opportunity optimistically. There was a lot of talk about China being the next engine of growth because it was open, pragmatic, and gradually aligning with Western economic practices. At that time, few expected that President Xi Jinping would later gain so much authority and steer the country in a more authoritarian direction.
Escalating tensions over Taiwan, supply chains, financial markets, and intellectual property are now making the region inherently less stable. Beijing's handling of Hong Kong has diminished confidence in China's commitment to a stable legal and business environment. China's aggressive moves in the South China Sea have worsened relations with the Philippines and created second thoughts among U.S. allies and regional powers. These concerns continue to mount amid President Trump’s unpredictable, unstable policies.
For healthcare companies, these geopolitical flashpoints create unreliable logistics, inconsistent regulations, disruptions to cross-border data flow, and long-term capital uncertainties. When boards and management teams consider expansion, they need to weigh these operational and investment risks, especially when other markets offer similar growth potential with less geopolitical risk.
From Engagement to Competition in Strategy
The deterioration of U.S.–China relations is not accidental nor superficial. It reflects evolving views on economic power, technological dominance, and legal stability. Export controls, investment restrictions, technology bans, and sanctions have become core components of long-term policy, especially in areas like healthcare, biotech, AI diagnostics, and data platforms.
These developments are particularly relevant for Asian firms operating globally or aiming to attract international investors. China's increasingly nationalistic policies prioritise domestic interests over market logic. Approval processes, data localisation requirements, procurement policies, and enforcement actions can change rapidly and often lack the transparency and fairness typical of Western countries. This complicates risk management and long-term investment decisions.
China is no longer easy to access; it has become complex and unpredictable. This growing uncertainty heightens the risk of falling into the "China trap."
Why Healthcare Is Especially Prone to the Trap
Healthcare is especially vulnerable to geopolitical tensions because it involves public policy, national resilience, data sovereignty, and population security. Unlike consumer goods or light manufacturing, healthcare enterprises rely on regulatory trust, strong institutional alliances, and reliable reimbursement systems.
Foreign healthcare firms in China face increasing pressure to localise intellectual property, bow to local authorities, and adhere to government policies that may not align with shareholder or patient interests. Money flows are still tightly controlled, and investments abroad or the repatriation of profits can be restricted, complicating exit strategies.
This environment hampers Asian companies’ ability to grow sales, enhance global reputation, increase valuation, and explore strategic options. Overexposure to China can also impede access to U.S. capital markets, Western partners, and international clients—all of whom are wary of the risks related to China.
The U.S. as a Strategic Counterbalance
In this situation, the United States remains a strong market and a stabilising force in the global economy. Donald Trump's recent executive leadership has been characterised by erratic language and sudden policy signals, frequently magnified by his volatile late-night social media posts. However, seasoned institutional participants recognise that most of this commotion fails to result in lasting structural transformation.
The basic structure of the U.S. system is still the same, even though the news is full of stories about its current executive leadership. Regulatory frameworks are clear, the rule of law is consistently upheld, and independent institutions maintain stability and predictability. Long term, the current U.S. executive leadership is only one-third of the U.S. government and one-fourth of the way through its four-year term. For businesses making long-term decisions about investments and growth, these basic facts remain crucial. The short-term political drama will end.
The U.S. remains the world’s largest healthcare market, seeking innovation in hospital management, digital health, diagnostics, and specialised treatments. Its norms, legal framework, and judicial scrutiny ensure a level playing field and predictable entry conditions. While U.S. regulations can be strict, they provide stability and confidence for strategic planning and investment.
Venture capital, private equity, strategic investors, and healthcare partners form part of the U.S. investment ecosystem, supporting sound governance, compliance, and long-term value creation. Asian companies tend to prioritise demonstrating commitment, credibility, and readiness for global expansion rather than immediate profits in the U.S. market. Firms heavily exposed to geopolitical risks often struggle to secure the partnerships and funding that U.S.-based companies easily access.
A New Approach for Asian Healthcare Firms
Rather than retreat, healthcare operators, technology providers, and investors in Asia should recalibrate their strategies. The U.S. offers a fertile ground for long-term growth aligned with global healthcare trends. The rewards for participating in this market can be substantial.
Establishing a U.S. footprint doesn't necessarily entail large upfront investments. Many successful Asian organisations start with targeted partnerships, modest investments, pilot projects, or skill acquisitions. Over time, these foundations can expand into significant market presence supported by U.S.-based leadership, compliance frameworks, and investor networks.
Navigating the Trap with Realistic Expectations
The "China trap" isn’t rooted in ideology or planned separation; it’s about recognising that political dynamics evolve faster than most business plans. Healthcare CEOs expecting China to remain a low-risk growth driver risk being caught off guard, especially when they need funding, partnerships, or exit options.
Strategically shifting investments towards the U.S. and allied markets positions companies for long-term value, resilience, and credibility. These qualities are crucial in healthcare, where trust, regulatory stability, and institutional alignment are as vital as innovation. The global healthcare system is moving away from just expanding the market and toward strategic alignment. China is still important, but it is no longer the only or best choice.
The U.S. is complex, but it remains stable, open, and closely linked to the world's top healthcare innovation and investment networks. For those who are open to changing their growth plans based on geopolitics, going west may be the best and most profitable way to go.
Dennis M. Sponer
Most Read Articles
